At the time of writing, Alnylam Pharmaceuticals Inc [ALNY] stock is trading at $283.40, up 5.92%. An important factor to consider is whether the stock is rising or falling in short-term value. The ALNY shares have gain 9.70% over the last week, with a monthly amount glided 22.72%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] stock has seen the most recent analyst activity on March 31, 2025, when Redburn Atlantic initiated its Buy rating and assigned the stock a price target of $353. Previously, JP Morgan upgraded its rating to Overweight on March 24, 2025, and elevated its price target to $328. On November 12, 2024, downgrade downgraded it’s rating to Underperform. Scotiabank started tracking the stock assigning a Sector Outperform rating. Goldman upgraded its rating to a Buy and raised its price target to $370 on August 16, 2024. Goldman downgraded its rating to Neutral for this stock on February 16, 2024, but kept the price target unchanged to $173. In a note dated February 15, 2024, Wolfe Research initiated an Peer Perform rating.
For the past year, the stock price of Alnylam Pharmaceuticals Inc fluctuated between $144.73 and $304.39. Currently, Wall Street analysts expect the stock to reach $324 within the next 12 months. Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] shares were valued at $283.40 at the most recent close of the market. An investor can expect a potential return of 14.33% based on the average ALNY price forecast.
Analyzing the ALNY fundamentals
According to Alnylam Pharmaceuticals Inc [NASDAQ:ALNY], the company’s sales were 2.35B for trailing twelve months, which represents an 20.20% jump. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.05%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.06, Equity is -5.09 and Total Capital is -0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 11.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 271.39 points at the first support level, and at 259.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 290.21, and for the 2nd resistance point, it is at 297.01.
Ratios To Look Out For
It is important to note that Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] has a current ratio of 3.04. On the other hand, the Quick Ratio is 2.98, and the Cash Ratio is 0.95. Considering the valuation of this stock, the price to sales ratio is 15.74, the price to book ratio is 319.92.
Transactions by insiders
Recent insider trading involved BONNEY MICHAEL W, Director, that happened on May 15 ’25 when 11250.0 shares were purchased. Director, Reitan Colleen F completed a deal on Aug 29 ’24 to buy 32.0 shares. Meanwhile, Director Reitan Colleen F bought 4.0 shares on Oct 17 ’24.
